Patent Application Titled "Heterodimeric Antibodies That Bind Cd3 And Gpc3" Published Online (USPTO 20240034815).
In: Pharma Business Week, 2024-02-23, S. 1286-1286
serialPeriodical
Zugriff:
The patent application titled "Heterodimeric Antibodies That Bind Cd3 And Gpc3" describes the development of bispecific antibodies that can target CD3 and GPC3, proteins associated with certain types of cancer. These antibodies have the potential to redirect CD3+ T cells to destroy cancer cells. The invention aims to improve upon previous attempts to target GPC3, such as CD3 bispecific antibodies and CAR-T therapies, which have shown adverse events in preclinical or clinical settings. The document provides details on the composition and structure of the antibodies, as well as methods for producing them. For more information, please refer to the full patent application. [Extracted from the article]
Copyright of Pharma Business Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Patent Application Titled "Heterodimeric Antibodies That Bind Cd3 And Gpc3" Published Online (USPTO 20240034815).
|
---|---|
Zeitschrift: | Pharma Business Week, 2024-02-23, S. 1286-1286 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6675 (print) |
Schlagwort: |
|
Sonstiges: |
|